VNL1 Stock Overview
An investment holding company, provides research and development services of drugs, bio drugs, natural drugs, and synthetic drugs in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
China Health Group Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.007 |
| 52 Week High | HK$0.012 |
| 52 Week Low | HK$0.001 |
| Beta | -2.32 |
| 11 Month Change | 180.00% |
| 3 Month Change | 366.67% |
| 1 Year Change | -41.67% |
| 33 Year Change | -77.42% |
| 5 Year Change | n/a |
| Change since IPO | -84.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| VNL1 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 366.7% | 2.9% | 0.8% |
| 1Y | -41.7% | -12.7% | 6.1% |
Return vs Industry: VNL1 underperformed the German Life Sciences industry which returned -12.7% over the past year.
Return vs Market: VNL1 underperformed the German Market which returned 6.1% over the past year.
Price Volatility
| VNL1 volatility | |
|---|---|
| VNL1 Average Weekly Movement | 186.3% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: VNL1's share price has been volatile over the past 3 months.
Volatility Over Time: VNL1's weekly volatility has increased from 95% to 186% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 42 | n/a | www.chgi.net |
China Health Group Inc., an investment holding company, provides research and development services of drugs, bio drugs, natural drugs, and synthetic drugs in the People’s Republic of China. The company offers contracted clinical research services; contracted pharmaceutical development services; and post launch market research, medical, and medical market services. It also provides hospital management, clinical research and promotion, and specialized hospital services, as well as Venturepharma health cloud; and tourism recovery services.
China Health Group Inc. Fundamentals Summary
| VNL1 fundamental statistics | |
|---|---|
| Market cap | €10.13m |
| Earnings (TTM) | -€7.38m |
| Revenue (TTM) | €2.72m |
3.7x
P/S Ratio-1.4x
P/E RatioIs VNL1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VNL1 income statement (TTM) | |
|---|---|
| Revenue | CN¥21.43m |
| Cost of Revenue | CN¥13.21m |
| Gross Profit | CN¥8.21m |
| Other Expenses | CN¥66.23m |
| Earnings | -CN¥58.01m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.058 |
| Gross Margin | 38.33% |
| Net Profit Margin | -270.78% |
| Debt/Equity Ratio | 0% |
How did VNL1 perform over the long term?
See historical performance and comparison